Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up
Biomarcadores; Fenotipo clásico; Enfermedad de Fabry
| Autores: | , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2021 |
| País: | España |
| Institución: | Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| Repositorio: | Recercat. Dipósit de la Recerca de Catalunya |
| OAI Identifier: | oai:recercat.cat:11351/6740 |
| Acceso en línea: | https://hdl.handle.net/11351/6740 |
| Access Level: | acceso abierto |
| Palabra clave: | Enzims - Regulació Marcadors bioquímics Metabolisme, Errors congènits del - Diagnòstic ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Enzyme Therapy::Enzyme Replacement Therapy DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Genetic Diseases, X-Linked::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Fabry Disease Other subheadings::Other subheadings::/diagnosis CHEMICALS AND DRUGS::Biological Factors::Biomarkers ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades genéticas ligadas al cromosoma X::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedad de Fabry Otros calificadores::Otros calificadores::/diagnóstico TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia enzimática::tratamiento de sustitución enzimática COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores |
| id |
ES_8da9145fbd2ab2ca4bcc710bd06dcbe3 |
|---|---|
| oai_identifier_str |
oai:recercat.cat:11351/6740 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up |
| title |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up |
| spellingShingle |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up Carnicer Cáceres, Clara Enzims - Regulació Marcadors bioquímics Metabolisme, Errors congènits del - Diagnòstic ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Enzyme Therapy::Enzyme Replacement Therapy DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Genetic Diseases, X-Linked::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Fabry Disease Other subheadings::Other subheadings::/diagnosis CHEMICALS AND DRUGS::Biological Factors::Biomarkers ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades genéticas ligadas al cromosoma X::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedad de Fabry Otros calificadores::Otros calificadores::/diagnóstico TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia enzimática::tratamiento de sustitución enzimática COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores |
| title_short |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up |
| title_full |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up |
| title_fullStr |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up |
| title_full_unstemmed |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up |
| title_sort |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-up |
| dc.creator.none.fl_str_mv |
Carnicer Cáceres, Clara Arranz Amo, José Antonio Cea Arestín, Cristina Camprodon Gomez, Maria Moreno Martinez, David Lucas del Pozo, Sara Moltó Abad, Marc Miquel Agraz Pamplona, Irene Hernández Vara, Jorge Armengol Bellapart, Mar del Toro Riera, Mireia Pintos Morell, Guillem Rodríguez Palomares, Jose Fernando Tigri-Santiña, Ariadna |
| author |
Carnicer Cáceres, Clara |
| author_facet |
Carnicer Cáceres, Clara Arranz Amo, José Antonio Cea Arestín, Cristina Camprodon Gomez, Maria Moreno Martinez, David Lucas del Pozo, Sara Moltó Abad, Marc Miquel Agraz Pamplona, Irene Hernández Vara, Jorge Armengol Bellapart, Mar del Toro Riera, Mireia Pintos Morell, Guillem Rodríguez Palomares, Jose Fernando Tigri-Santiña, Ariadna |
| author_role |
author |
| author2 |
Arranz Amo, José Antonio Cea Arestín, Cristina Camprodon Gomez, Maria Moreno Martinez, David Lucas del Pozo, Sara Moltó Abad, Marc Miquel Agraz Pamplona, Irene Hernández Vara, Jorge Armengol Bellapart, Mar del Toro Riera, Mireia Pintos Morell, Guillem Rodríguez Palomares, Jose Fernando Tigri-Santiña, Ariadna |
| author2_role |
author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Institut Català de la Salut [Carnicer-Cáceres C, Arranz-Amo JA, Cea-Arestin C] Laboratori d'Errors Innats del Metabolisme, Laboratoris Clínics, Vall d’Hebron Hospital, Barcelona, Spain. [Camprodon-Gomez M] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Moreno-Martinez D] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust and University College London, London WC1E 6BT, UK. [Lucas-Del-Pozo S] Laboratori de Malalties Neurodegeneratives, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK. [Moltó-Abad M] Validació Funcional i Investigació Preclínica, Distribució de Fàrmacs i Grup d'Orientació, CIBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain. [Tigri-Santiña A] Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Agraz-Pamplona I] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Rodriguez-Palomares JF] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hernández-Vara J, Armengol-Bellapart M] Laboratori de Malalties Neurodegeneratives, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Del-Toro-Riera M] Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Neurologia Pediàtrica, Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pintos-Morell G] Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Validació Funcional i Investigació Preclínica, Distribució de Fàrmacs i Grup d'Orientació, CIBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain Vall d'Hebron Barcelona Hospital Campus |
| dc.subject.none.fl_str_mv |
Enzims - Regulació Marcadors bioquímics Metabolisme, Errors congènits del - Diagnòstic ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Enzyme Therapy::Enzyme Replacement Therapy DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Genetic Diseases, X-Linked::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Fabry Disease Other subheadings::Other subheadings::/diagnosis CHEMICALS AND DRUGS::Biological Factors::Biomarkers ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades genéticas ligadas al cromosoma X::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedad de Fabry Otros calificadores::Otros calificadores::/diagnóstico TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia enzimática::tratamiento de sustitución enzimática COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores |
| topic |
Enzims - Regulació Marcadors bioquímics Metabolisme, Errors congènits del - Diagnòstic ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Enzyme Therapy::Enzyme Replacement Therapy DISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Genetic Diseases, X-Linked::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Fabry Disease Other subheadings::Other subheadings::/diagnosis CHEMICALS AND DRUGS::Biological Factors::Biomarkers ENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades genéticas ligadas al cromosoma X::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedad de Fabry Otros calificadores::Otros calificadores::/diagnóstico TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia enzimática::tratamiento de sustitución enzimática COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadores |
| description |
Biomarcadores; Fenotipo clásico; Enfermedad de Fabry |
| publishDate |
2021 |
| dc.date.none.fl_str_mv |
2021 2021 2021 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
https://hdl.handle.net/11351/6740 |
| url |
https://hdl.handle.net/11351/6740 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
Journal of Clinical Medicine;10(8) https://doi.org/10.3390/jcm10081664 |
| dc.rights.none.fl_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess |
| rights_invalid_str_mv |
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf application/pdf |
| dc.publisher.none.fl_str_mv |
MDPI |
| publisher.none.fl_str_mv |
MDPI |
| dc.source.none.fl_str_mv |
Scientia reponame:Recercat. Dipósit de la Recerca de Catalunya instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| instname_str |
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) |
| reponame_str |
Recercat. Dipósit de la Recerca de Catalunya |
| collection |
Recercat. Dipósit de la Recerca de Catalunya |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869413064266219520 |
| spelling |
Biomarkers in Fabry Disease: Implications for Clinical Diagnosis and Follow-upCarnicer Cáceres, ClaraArranz Amo, José AntonioCea Arestín, CristinaCamprodon Gomez, MariaMoreno Martinez, DavidLucas del Pozo, SaraMoltó Abad, Marc MiquelAgraz Pamplona, IreneHernández Vara, JorgeArmengol Bellapart, Mardel Toro Riera, MireiaPintos Morell, GuillemRodríguez Palomares, Jose FernandoTigri-Santiña, AriadnaEnzims - RegulacióMarcadors bioquímicsMetabolisme, Errors congènits del - DiagnòsticANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Enzyme Therapy::Enzyme Replacement TherapyDISEASES::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Genetic Diseases, X-Linked::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Congenital, Hereditary, and Neonatal Diseases and Abnormalities::Genetic Diseases, Inborn::Fabry DiseaseOther subheadings::Other subheadings::/diagnosisCHEMICALS AND DRUGS::Biological Factors::BiomarkersENFERMEDADES::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades genéticas ligadas al cromosoma X::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas::enfermedad de FabryOtros calificadores::Otros calificadores::/diagnósticoTÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia enzimática::tratamiento de sustitución enzimáticaCOMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::biomarcadoresBiomarcadores; Fenotipo clásico; Enfermedad de FabryBiomarkers; Classic phenotype; Fabry diseaseBiomarcadors; Fenotip clàssic; Malaltia de FabryFabry disease (FD) is a lysosomal storage disorder caused by deficient alpha-galactosidase A activity in the lysosome due to mutations in the GLA gene, resulting in gradual accumulation of globotriaosylceramide and other derivatives in different tissues. Substrate accumulation promotes different pathogenic mechanisms in which several mediators could be implicated, inducing multiorgan lesions, mainly in the kidney, heart and nervous system, resulting in clinical manifestations of the disease. Enzyme replacement therapy was shown to delay disease progression, mainly if initiated early. However, a diagnosis in the early stages represents a clinical challenge, especially in patients with a non-classic phenotype, which prompts the search for biomarkers that help detect and predict the evolution of the disease. We have reviewed the mediators involved in different pathogenic mechanisms that were studied as potential biomarkers and can be easily incorporated into clinical practice. Some accumulation biomarkers seem to be useful to detect non-classic forms of the disease and could even improve diagnosis of female patients. The combination of such biomarkers with some response biomarkers, may be useful for early detection of organ injury. The incorporation of some biomarkers into clinical practice may increase the capacity of detection compared to that currently obtained with the established diagnostic markers and provide more information on the progression and prognosis of the disease.The research has not received any external funding.MDPIInstitut Català de la Salut[Carnicer-Cáceres C, Arranz-Amo JA, Cea-Arestin C] Laboratori d'Errors Innats del Metabolisme, Laboratoris Clínics, Vall d’Hebron Hospital, Barcelona, Spain. [Camprodon-Gomez M] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Moreno-Martinez D] Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Lysosomal Storage Disorders Unit, Royal Free Hospital NHS Foundation Trust and University College London, London WC1E 6BT, UK. [Lucas-Del-Pozo S] Laboratori de Malalties Neurodegeneratives, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London WC1N 3BG, UK. [Moltó-Abad M] Validació Funcional i Investigació Preclínica, Distribució de Fàrmacs i Grup d'Orientació, CIBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), 08035 Barcelona, Spain. [Tigri-Santiña A] Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Agraz-Pamplona I] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Rodriguez-Palomares JF] Servei de Cardiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hernández-Vara J, Armengol-Bellapart M] Laboratori de Malalties Neurodegeneratives, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Del-Toro-Riera M] Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Servei de Neurologia Pediàtrica, Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pintos-Morell G] Unitat de Malalties Metabòliques Hereditàries, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Validació Funcional i Investigació Preclínica, Distribució de Fàrmacs i Grup d'Orientació, CIBIM-Nanomedicina, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, SpainVall d'Hebron Barcelona Hospital Campus202120212021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11351/6740Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésJournal of Clinical Medicine;10(8)https://doi.org/10.3390/jcm10081664Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/67402026-05-29T05:05:01Z |
| score |
15,30478 |